Fentanyl transdermal - Janssen Pharmaceutical KK

Drug Profile

Fentanyl transdermal - Janssen Pharmaceutical KK

Alternative Names: Durotep; JNJ-35685-AAA-G016; JNJ-35685-AAA-G021; JNS-020; JNS-020QD

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Pharmaceutical KK
  • Developer Janssen Pharmaceutical KK; Janssen Research & Development
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain
  • Discontinued Cancer pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in Belgium (Transdermal, Patch)
  • 01 Jun 2016 Janssen Research & Development completes a phase I trial in Healthy volunteers in USA (NCT02617758)
  • 01 Apr 2016 Janssen Research & Development completes a phase I trial in Pain (In volunteers) in USA (NCT02608320)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top